

PF4908

Abstract

The invention relates to novel aminothiazole derivatives which are inhibitors of the transforming growth factor, ("TGF")- $\beta$  signalling pathway, in particular, the phosphorylation of smad2 or smad3 by the TGF- $\beta$  type I or activin-like kinase ("ALK")-5 receptor, methods for their preparation and their use in medicine, specifically in the treatment and prevention of a disease state mediated by this pathway.


**REMARKS**

This Preliminary Amendment is being made upon entry of International Application No. PCT/EP03/08385 into the U.S. National Phase of prosecution. In the specification, a new paragraph has been added to the first line of the specification to include the priority information. An Abstract on a separate sheet is attached as required under 37 CFR 1.72(b).

Claims 4-6, 8-11 and 14 have been amended. Claims 15-18 have been canceled. New claim 19 has been added and is directed to a method of treatment and prophylaxis of specific diseases comprising administering a compound of formula I.

Favorable reconsideration of claims 4-6, 8-11 and 14, favorable consideration of new claim 19 and allowance of this application with claims 1-14 and 19 are earnestly solicited.

Respectfully submitted,



Nora Stein-Fernandez  
Attorney for Applicants  
Registration No. 36,689

GLAXOSMITHKLINE  
Corporate Intellectual Property UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5044  
Facsimile (610) 270-5090